Two stage open label followed by placebo controlled Phase 2 study of Pracinostat and Azicitidine in paitents with IPSS-R High and Very High Risk MDS untreated with HMA’s

Sponsor
Helsinn Healthcare SA

Protocol Number
MEI-011

To Learn More Call
201-510-0910